LPCN Relative Valuation
LPCN's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, LPCN is overvalued; if below, it's undervalued.
Historical Valuation
Lipocine Inc (LPCN) is now in the Undervalued zone, suggesting that its current forward PS ratio of 0.00 is considered Undervalued compared with the five-year average of -4.81. The fair price of Lipocine Inc (LPCN) is between +Inf to +Inf according to relative valuation methord. Compared to the current price of 3.09 USD , Lipocine Inc is Undervalued By Fair.
Relative Value
Fair Zone
+Inf-+Inf
Current Price：3.09
Fair
Undervalued
-1.30
PE
1Y
3Y
5Y
Trailing
Forward
0.00
EV/EBITDA
Lipocine Inc. (LPCN) has a current EV/EBITDA of 0.00. The 5-year average EV/EBITDA is 0.08. The thresholds are as follows: Strongly Undervalued below -0.47, Undervalued between -0.47 and -0.19, Fairly Valued between 0.36 and -0.19, Overvalued between 0.36 and 0.63, and Strongly Overvalued above 0.63. The current Forward EV/EBITDA of 0.00 falls within the Historic Trend Line -Fairly Valued range.
-0.17
EV/EBIT
Lipocine Inc. (LPCN) has a current EV/EBIT of -0.17. The 5-year average EV/EBIT is -2.12. The thresholds are as follows: Strongly Undervalued below -9.02, Undervalued between -9.02 and -5.57, Fairly Valued between 1.33 and -5.57, Overvalued between 1.33 and 4.78, and Strongly Overvalued above 4.78. The current Forward EV/EBIT of -0.17 falls within the Historic Trend Line -Fairly Valued range.
41.24
PS
Lipocine Inc. (LPCN) has a current PS of 41.24. The 5-year average PS is 17.23. The thresholds are as follows: Strongly Undervalued below -19.50, Undervalued between -19.50 and -1.14, Fairly Valued between 35.60 and -1.14, Overvalued between 35.60 and 53.96, and Strongly Overvalued above 53.96. The current Forward PS of 41.24 falls within the Overvalued range.
-1.86
P/OCF
Lipocine Inc. (LPCN) has a current P/OCF of -1.86. The 5-year average P/OCF is -7.14. The thresholds are as follows: Strongly Undervalued below -31.35, Undervalued between -31.35 and -19.24, Fairly Valued between 4.97 and -19.24, Overvalued between 4.97 and 17.07, and Strongly Overvalued above 17.07. The current Forward P/OCF of -1.86 falls within the Historic Trend Line -Fairly Valued range.
0.00
P/FCF
Lipocine Inc. (LPCN) has a current P/FCF of 0.00. The 5-year average P/FCF is 5.00. The thresholds are as follows: Strongly Undervalued below -36.17, Undervalued between -36.17 and -15.59, Fairly Valued between 25.59 and -15.59, Overvalued between 25.59 and 46.18, and Strongly Overvalued above 46.18. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.
Lipocine Inc (LPCN) has a current Price-to-Book (P/B) ratio of 1.18. Compared to its 3-year average P/B ratio of 1.03 , the current P/B ratio is approximately 15.12% higher. Relative to its 5-year average P/B ratio of 1.87, the current P/B ratio is about -36.61% higher. Lipocine Inc (LPCN) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -36.22%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -25.64% , the current FCF yield is about -100.00% lower.
1.19
P/B
Median3y
1.03
Median5y
1.87
-30.02
FCF Yield
Median3y
-36.22
Median5y
-25.64
Competitors Valuation Multiple
The average P/S ratio for LPCN's competitors is 1.02, providing a benchmark for relative valuation. Lipocine Inc Corp (LPCN) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of LPCN decreased by 36.48% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 0.00 to 114.57K.
The secondary factor is the Margin Expansion, contributed 11982.80%to the performance.
Overall, the performance of LPCN in the past 1 year is driven by Revenue Growth. Which is more sustainable.
People Also Watch
FAQ
Is Lipocine Inc (LPCN) currently overvalued or undervalued?
What is Lipocine Inc (LPCN) fair value?
How does LPCN's valuation metrics compare to the industry average?
What is the current P/B ratio for Lipocine Inc (LPCN) as of Dec 05 2025?
What is the current FCF Yield for Lipocine Inc (LPCN) as of Dec 05 2025?
What is the current Forward P/E ratio for Lipocine Inc (LPCN) as of Dec 05 2025?